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YESTERDAY
Phenotypic syndromes were the first immunodeficiency syndromes described (Table I ), usually without noting the patients' increased susceptibility to infection. These date from the 1920s when Syllaba and Henner (2) in Paris described ataxia-telangiectasia and Thorpe and Handley (3) in Philadelphia described mucocutaneous candidiasis. Ataxia-telangiectasia was rediscovered in 1941 by Madame Louis-Bar (4) in Paris and again in 1957 by Boder and Sedgwick (5) in Los Angeles.
In the 1930s, Wiskott (6) in Munich, Germany, identified what is now known as the Wiskott-Aldrich syndrome; this was independently rediscovered in 1954 when Aldrich et al. (7) , in Rochester, Minnesota, wrote an article on the subject in English. Glanzmann and Riniker's 1950 paper from Bern, Switzerland, described a fatal case of severe combined immunodeficiency, noting the lymphopenia that accompanied the disorder (8) . The 1953 paper of Keidan et al. (9) from Liverpool, UK, described fatal progressive vaccinia in a child with lymphopenia and agammaglobulinemia. The syndrome was further elucidated when siblings of the patient reported in the original paper were again described from Bern in 1958, providing the eponym "Swiss-type agammaglobulinemia" (10, 1 1). Agammaglobulinemia in a 39-y-old woman (common variable immunodeficiency) was first described by Sanford et al. (1 2) 
in 1954.
A disorder of the phagocytic system was first identified in 1957 by the Minneapolis group, who described chronic granulomatous disease under the pessimistic name "fatal granulomatous disease of childhood" (13) . To complete the discovery of the main types of immunodeficiency, hereditary C2 deficiency with infection was first described in 1965 by Klemperer et al. (1 4) . References from Ross and Densen's marvelous review (15) of the complement deficiency syndromes provide the information necessary to construct a unique schema, the complement deficiency discovery pathway (Fig. I) , starting in 1965 with C2 deficiency (14) and appropriately terminating with C9 deficiency (1 6) 
in 1983.
This brief historical review ends with DiGeorge's description of thymic hypoplasia in 1965 (17) , the same year in which this author finished a fellowship and sought gainful employment, thus ending yesterday and starting today.
The conventional wisdom concerning the birth of immunodeficiency is that this blessed event occurred in 1952 with Bru-TODAY ton's description of congenital agammaglobulinemia (1) . In one Today's immunodeficiencies are defined, for this overview, as respect this is true, in another, not so. Agammaglobulinemia those covered in my text, Immunologic Diseases in Infants and clearly was the first immunodeficiency described that necessi-Children, published in 1973, 1980, 1989 , and hopefully 1994 tated an immunologic test (in this Case Tiselius' serum electr0- (18) (19) (20) (21) . The overall incidence of primary immunodeficiency phoresis) to identify the disease and devise a treatment (gamma probably has not changed in this two-decade period, remaining globulin injections). However, several phenotypic syndromes, at about 1 per 10 000 live births (excluding IgA deficiency). now known to have major immunologic defects, were described However, a larger number of primary immunodeficiencies are many years before Bruton's report (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) .
recognized and more patients are surviving so that the total In this article, I review some historical Papers on primary number of cases is increasing slowly. As the diverse cells and immunodeficiency (yesterday), discuss some trends in Present molecules of the immune system are identified and their interday immunology (today), and project some dkorders of immu-actions explored, more and more distinct disorders have been nity that will be forthcoming in the next several years (tomorrow). defined. increased dramatically. This can be attributed to such factors as 1 ) increased survival of tiny premature infants and a longer life span, leading to the immunodeficiencies of immaturity and aging; 2) increased use and number of immunosuppressive agents (drugs, radiation, plasmapheresis); 3) better treatment of primary diseases (infections, cancers) with prolonged survival; 4) more transplant procedures; 5) better diagnosis of subtle immunodeficiencies; 6) global malnutrition; and 7) the AIDS epidemic.
The growth of immunodeficiency can be readily illustrated by recording the number of primary and secondary immunodeficiency syndromes described in the 1st edition of my text, published in 1973 (IS), compared to the 3rd edition, published in 1989 (20) . In 1973, nine secondary and 34 primary immunodeficiencies were described, compared to 28 secondary and 66 primary immunodeficiencies in 1989 (Table 2 ). This means that investigators discovered about two new primary and one new secondary immunodeficiencies annually. As the next edition will indicate, this discovery pattern continues unabated, involving all limbs of the immune system except for complement deficiencies, inasmuch as no new complement components have been added.
Some of the major areas of progress in the field in the last two decades are identified in Almost as interesting as the new advances were the blind alleys. As noted in Table 4 , these include diagnoses that are in question (C5 dysfunction) or belong to a better-defined syndrome (the patient with actin dysfunction had leukocyte adhesion deficiency) or have never been confirmed. Certain treatments have been shown to be ineffective (transfer factor) or replaced by better therapies (fetal liver transplantation). Some of these may be resurrected with further refinements (thymic hormone therapy) or under limited circumstances (IgA-deficient plasma for severe IgA sensitivity in a patient who needs immune globulin treatment).
TOMORROW
I have identified six new groups of immunodeficiencies ( Table  5 ) that are as yet unreported in my textbook, but that will be discussed in the next edition. Some of these disorders are new; others have been around for some time, but their description has not been recognized as part of the main stream of immunologic information. AIDS is another of tomorrow's immunodeficiencies, just as it is today's immunodeficiency. The number of papers on AIDS is increasing as rapidly as the spread of the epidemic; these efforts will continue to expand the knowledge of the cause and consequences of T-cell immunodeficiency.
The first group to be considered are the familial neutropenic syndromes with hypogammaglobulinemia as summarized in Table 6 . This table is derived from a recent article by Wetzler et al. (22) and includes their description of a new familial neutropenic syndrome: the WHIM syndrome. This is an illness described in two sisters (aged 22 and 23) who had Warts, Hypogammaglobulinemia,~nfections, and Myelokathexis, the latter referring to retention of leukocytes within a hypercellular marrow. Ig and B cells were low but not absent in the patients, and mitogeninduced proliferative responses and delayed hypersensitivity tests were somewhat decreased. The bone marrow was hypercellular with a shift to the right and many mature myeloid cells.
This and other hereditary immunodeficiencies with neutropenia emphasize the close relationship between the immune system and the control of myelopoiesis. High-dose i.v. immune globulin therapy often reverses the neutropenia in patients with X-linked agammaglobulinemia and the hyper-IgM syndrome. A unifying hypothesis is sorely needed.
A second group of intriguing immunodeficiencies are the phenotypic genetic syndromes with immune abnormalities. Table 7 details several familiar and not so familiar syndromes that almost always have one or more immune defects. Bloom's syndrome and Schimke's immuno-osseous dysplasia are new arrivals on this list and deserve some comment.
Bloom's syndrome (23) (24) (25) (26) (27) is an autosomal recessive syndrome of growth retardation, peculiar physiognomy, hypogonadism, and telangiectatic erythema of the face associated with sun sensitivity. There is a high frequency of chromoscme breakage and increased risk for the development of lymphoid malignancy. Several papers have detailed the immunologic abnormalities associated with Bloom's syndrome, accounting for increased susceptibility to infection beginning early in life. These include 12-y-old male with Hodgkin's; 6-y-old brother has respiratory infection and adenopathy Hassall's corpuscles and abnormal histology. This illness emphasizes the common association of skeletal and immune system abnormalities (30) . Several other genetic syndromes are reported with inconsistent immune abnormalities ( Table 8) . Most have T-cell defects, although chromosome 18 abnormalities have IgA deficiency. As these defects are localized to specific chromosomes or chromosome regions, multiple regulatory interactions within the T-cell system will become better defined. A third new group of immunodeficiencies are the NK cell defects outlined in Table 9 . These can be divided into three groups: 1 ) well-recognized immunodeficiencies whose immunologic defect includes NK deficiency, 2) miscellaneous syndromes in which NK deficiency has been identified, and 3) primary immunodeficiencies due to absent or decreased NK function.
Primary immunodeficiencies may have an NK defect as part of a generalized defect in lymphocyte development, such as in severe combined immunodeficiency or reticular dysgenesis (4 1, 42). Lack of a specific surface glycoprotein on all leukocytes prevents target cell binding and decreased cytotoxicity in the leukocyte adhesion deficiency syndrome (48). The best described and most consistent NK deficiency occurs in the ChediakHigashi syndrome (44) (45) (46) (47) ; this is associated with a normal number of NK cells but delayed postbinding lysis (47) .
Several other illnesses have been noted to have depressed NK activity ( Table 9 ). The relationship of the NK deficit to the pathogenesis of these disorders is often obscure; in AIDS, however, it may be associated with progression of illness.
Seven patients with frequent severe infections who have an isolated NK defect have been described (Table 9 ). The patient described by Biron et al. (58) with recurrent otitis and severe herpes infection (life threatening varicella) is particularly interesting; she had neither NK cells, NK precursors, nor NK function, but except for recurrent neutropenia all other immune tests were normal.
A fourth group of illnesses are T-cell membrane defects (Table  10) . These all have defective T-cell activation with poor prolif- Table 12 . Earlv onset erative responses to mitogens and antigens, variable T-cell functional deficiency, and mild to severe susceptibility to infection (60) (61) (62) (63) . Two of these patients have a structurally abnormal TCR; one lacked the CD3-{ chain (60) , and the second had deficient a/@ TCR-CD3 cells and a great excess of y/6 TCR-CD3 cells (6 1).
The lymphocyte defect of one of the two patients with abnormal signal transduction could be corrected by calcium ionophore and phorbol, suggesting a defect in signal generation coupled to the G-protein second messenger system (62) . In the second patient (63) , the exact defect of signal transduction could not be identified, but there were abnormally high intracellular Ca++ and phosphatidylcholine/phosphatidylserine ratio after phytohemagglutinin proliferation. In all these cases, failure of T-lymphocyte activation occurs, leading to immunodeficiency. Because of the complexity of the activation pathway, many more defects will undoubtedly be identified.
The fifth new area of immunodeficiency is deficient production of specific cytokines, now numbering well over 15 examples. These defects are particularly important to identify because they may sometimes be treated by administration of a recombinant form of the missing cytokine.
The best described IL defect involves deficiency of IL-2 (64-68). The clinical histories of four such infants are shown in Table  11 . All had partial or severe T-cell deficiency. One child improved dramatically with IL-2 therapy (66). Defective mRNA production for IL-2, IL-3, IL-4, and IL-5 was noted in one patient. It is of interest that IL-2 deficiency is compatible with prolonged survival and partially intact immune function.
Undoubtedly, other IL defects will be found. Multiple IL may be reduced in X-linked agammaglobulinemia and common variable immunodeficiency, but whether they represent the fundamental defect is not known. In addition, several patients (56) have deficient interferon-y synthesis as well as decreased NK function. Excessive IL-6 synthesis may be present in hyper-IgE syndrome and Castleman's disease (69) .
Phagocytic defects constitute the final group of new immunodeficiencies. Leukocyte adhesion deficiency has been described previously; much new information about this disorder is now available. One phagocytic deficiency syndrome that is not well described is early onset periodontal disease syndrome as summarized in Table 12 . There are two forms of this disease; both have early onset of periodontitis with tooth and alveolar bone loss. This may be associated with an abnormality of a neutrophil surface protein (gpllO) and a severe chemotactic defect (70) .
The latest syndrome to be described is asplenia, the congenital absence of the spleen. Wang and Hsieh (71) have identified a subtle T-cell defect, in addition to the expected decrease in phagocytosis of opsonized cells and bacteria. The role of tuftsin in this disorder needs clarification. There may be an associated antibody defect to polysaccharide antigens (72).
Tomorrow's defects, being only a day away, can be anticipated with some certainty. What illnesses will emerge the day after tomorrow are much more problematic. Recognizing and treating them are tasks for the next generation of pediatric investigators. Dr. Boxer: Tuftsin deficiency was originally described by Nadger from Tufts in the 1970s. Employing Tom Stossel's quantitative assay for phagocytosis, one cannot demonstrate any enhancement of phagocytosis. I think tuftsin deficiency is truly an artifact.
I would like to comment on the phagocytic disorders, some of them which you dismissed and some which you said are new. First of all, I believe the actin dysfunction, which Tom Stossel and I described in 1974 before monoclonal antibodies were available, is a distinct abnormality. In a paper published in Blood last year, Tom Coates and Tom Howard described another patient who apparently lacks the 47-kD cytoplasmic protein that is involved in actin regulation. We studied our particular patient with Harvey Colten and looked at complement receptors on the surface of the child's neutrophils. This child had many of the similar phenotypes of the lab patients, but did have receptors for complement, and his monocytes appeared to phagocytose particles. There was a clear-cut abnormality in the ability of the child's neutrophil actin to polymerize, which is not the case with the lab patients. Therefore, I would not dismiss the actin dysfunction syndrome.
The lazy leukocyte syndrome, described by Spike Miller in Lancet, was the first observation of a chemotactic defect. It was a descriptive disorder of myeloid hyperplasia in the bone marrow and the failure of release of neutrophils into the circulation; Miller then showed a chemotactic defect. Recently, David Dale and I had an opportunity to review 125 bone marrows of patients that had been randomized as part of the G-CSF (granulocyte colony-stimulating factor) trial for the treatment of neutropenic patients. We found three patients who, at least clinically, fit the lazy leukocyte syndrome. They had marrow hyperplasia with maturation right up through the neutrophil form and failure of release of neutrophils into the circulation. Myelokathexis, the WHIM syndrome, was originally described by Wolf Zuelzer in the New England Journal ofMedicine in the 1970s. It is a distinct abnormality in morphology of the neutrophils. The lobes of the segmented neutrophils are connected by thin filaments and one sees binucleated myelocytes and promyelocytes. In our study with the neutropenic patients, we have identified three patients with the WHIM syndrome. I do not think the two patients in Texas have a distinct syndrome different from the one Zuelzer described.
Dr. Schwartz: Dr. Stiehm, as you know, levamisole has now been approved for use as adjuvant therapy in colon carcinoma. Now that it is available without going through various INDs etc., we have had the chance to look at a couple of patients with Lany Boxer. Quite some time ago, Savita Pahwa and I saw some patients with T-cell deficiencies who seemed to respond reasonably well to levamisole. And of course the clinical trials that were used to substantiate its use for adjuvant therapy of colon carcinoma suggested that levamisole does have immunopotentiating activity. You might want to keep a reference to it in the fourth edition of your book.
Dr. Gupta: We are evaluating a patient with what might be a new syndrome. I would like to know if anyone in the audience has a similar case. In addition to what one finds in the WHIM syndrome, our patient, a young lady, presented with more generalized symptoms with some increase in upper respiratory tract infection, hypogammaglobulinemia, neutropenia, and thrombocytopenia. We are looking at the defects in more detail in this patient. There is no evidence of any malignancy, lymphoma, or an immunoglobulin gene variant, so we may be looking at another immunodeficiency.
Dr. Filipolvich: You mentioned transplant recipients-do you have any composite information on infants of former transplant recipients who were receiving continuous immunosuppression during the pregnancy? Dr. Stiehm: No, I have not. That is an interesting question though.
Dr. Filipolvich: We have one patient whom we have followed now for 4 y who was born to a mother who had received a renal graft and was on cyclosporine and immuran during the entire pregnancy. The baby was born at 34 wk with no white cells whatsoever, was T-cell deficient during the first year of life, but now at 4 y is indistinguishable from normal. Dr. Stiehm: That is very interesting. Dr. Ochs: Dr. Stiehm, since you mentioned some of the controversial syndromes of yesterday, I think we should also talk about some of the controversial syndromes of the future. Would you comment on the so-called chronic fatigue syndrome, which, in the literature at least, is being more and more associated with some not-so-well-defined T-cell abnormalities.
Dr. Stiehm: Yes, chronic fatigue syndrome is really mysterious. Dr. Jay Levy, who is in the audience, has studied this syndrome, but, as someone said, it is really hard to find an organic disease that occurs only in college-educated, upper middle class, white women, but that is the epidemiology of chronic fatigue syndrome. I have seen about 30 or 40 patients who were referred to me and have looked for immunologic abnormalities. Thus far I have not seen any. However, I think that there are investigators who do see immunologic abnormalities in these patients. Maybe Dr. Levy would like to comment.
Dr. Levy: I have not seen the immunologic defects that have been described in chronic fatigue syndrome, but I think we have to stay away from that subject. It is very controversial. In my experience, the patients with chronic fatigue syndrome are not all college-age. Let me say that in Japan there are a large number of cases of what they are calling NK-cell-deficiency syndrome. The chronic fatigue syndrome can also be seen in depression and bereavement.
I have another question. Maybe the information is not available, but would you speculate as to how many of these syndromes have led to the discovery of new growth factors, new membrane proteins, or new functions of cells? In other words, if one started from the syndrome, has it led to something that was not known, s8 STIEHM rather than taking something that was known and then asking if there was a defect? Dr. Stiehm: You make a very good point. Initially, of course, clinical observations triggered the immunologic findings, as with agammaglobulinemia. Nowadays, most of the obvious syndromes have been discovered. and we are now reversing ourselves in finding the defects first and then finding a patienlt that has those defects.
Dr. Strober: Just a comment about primary NK-cell deficiency. Patients with X-linked immunodeficiency syndrome, for instance, very frequently have reduced NK function, and when you look at these patients, they have very poor lymphokine production. It is probable that this is a secondary phenomenon. I feel that the burden of proof is on us to show that there is really a primary NK-cell deficiency, rather than one that is secondary t o some much more broadly based abnormality.
Dr. Levy: In my experience, it seems that the chronic fatigue syndrome is a real entity, but I think it is going to turn out to be a mixed bag. The current Annals of Internal Medicine includes an analysis of the Lake Tahoe epidemic of chronic fatigue syndrome, which was originally billed as an EBV (Epstein-Barr virus) infection but later turned out not to be. Robert Gallo, whose name is on the paper, claims to have grown out herpes virus 6 (HHV-6) from a very large percentage of the cells of those patients; whether that is causative or secondary is unclear. Dr. Frank: What was reported was an abnormality of cells that looked like they were infected by HHV-6, but were actually large macrophages. Before we get carried away with HHV-6, we should beware of observations which are reported on a morphologic basis rather than on real serologic information.
Dr. Levy: The authors did not make the claim that it was causative. In my former position, in the Laboratory of Clinical Investigation, Steve Strauss admitted a fair number of patients with chronic fatigue syndrome, and it was clear that those patients had something. What they have is very unclear, but I think it would be premature to dismiss chronic fatigue syndrome as simply a psychiatric disorder.
